The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesYafei Liu, Hisashi Arase, Noriko Arase et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 38
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesRyo Shinnakasu, Tomohiro Kurosaki, Shuhei Sakakibara et al.|The Journal of Experimental Medicine|2021Cited by 34
Secretory glycoprotein NS1 plays a crucial role in the particle formation of flavivirusesTomokazu Tamura, Yoshiharu Matsuura, Shuhei Taguwa et al.|PLoS Pathogens|2022Cited by 15